Antituberculosis drug resistance: practical solutions to practical problems

References

1. World Bank World development report: investing in health. New York: Oxford University Press; 1993116
   [Google Scholar]
2. Dolin P. J., Raviglione M. C., Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 1994; 72:213–220
   [Google Scholar]
3. Chaulet P., Raviglione M., Bustreo F. Epidemiology, control and treatment of multidrug-resistant tuberculosis. Drugs 1996; 52: Suppl 2103–108
   [Google Scholar]
4. Medical Research Council Streptomycin treatment of pulmonary tuberculosis. BMJ 1948; 2:769–782
   [Google Scholar]
5. Lehmann J. Para-aminosalicylic acid in the treatment of tuberculosis. Lancet 1946; 1:15–16
   [Google Scholar]
6. A Medical Research Council Investigation Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid. BMJ 1950; 2:1073–1085
   [Google Scholar]
7. A report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee Long-term chemotherapy in the treatment of chronic pulmonary tuberculosis with cavitation. Tubercle 1962; 43:201–267
   [Google Scholar]
8. Mazouni L., Zidouni N., Boulahbal F., Chaulet P. Treatment of failure and relapse cases of pulmonary tuberculosis within a national programme based upon short course chemotherapy. TRSU Progress Report 1992; 1:36–42
   [Google Scholar]
9. Crofton J., Chaulet P., Maher D. Guidelines on the management of drug resistant tuberculosis. WHO/TB/96.210. World Health Organization; Geneva: 1996
   [Google Scholar]
10. Upplekar M. W., Shepard D. S. Treatment of tuberculosis by private general practitioners in India. Tubercle 1991; 72:284–290
    [Google Scholar]
11. Mahmoudi A., Iseman M. D. Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. JAMA 1993; 270:65–68
    [Google Scholar]
12. Sumartojo E. When tuberculosis treatment fails. A social behavioural account of patient adherence. Am Rev Respir Dis 1993; 147:1311–1320
    [Google Scholar]
13. Acocella G. Human bioavailability studies. Bull Int Union Tuberc Lung Dis 1989; 64:38–40
    [Google Scholar]
14. Cohn D. L., Bustreo F., Raviglione M. C. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. Clin Infect Dis 1997; 24: Suppl 1S121–S130
    [Google Scholar]
15. Nuyangulu D. S., Nkhoma W. N., Salaniponi F. M. L. Factors contributing to a successful control programme in Malawi. Bull Int Union Tuberc Lung Dis 1990; 66: Suppl 45-4645–47
    [Google Scholar]
16. Kim S. J., Hong Y. P. Drug resistance in Mycobacterium tuberculosis in Korea. Tuber Lung Dis 1992; 73:219–224
    [Google Scholar]
17. Zhang L. X., Kan G. Q., Tu D. H., Li J. S., Liu X. X. Trend of initial drug resistance of tubercle bacilli isolated from new patients with pulmonary tuberculosis and its correlation with the tuberculosis programme in Beijing. Tuber Lung Dis 1995; 76:100–103
    [Google Scholar]
18. Frieden T. F., Fujiwara P. I., Washko R. M., Hamburg M. A. Tuberculosis in New York City. Turning the tide. N Engl J Med 1995; 333:229–233
    [Google Scholar]
19. Weis S. E., Slocum P. C., Blais F. X. The effect of directly observed therapy on the rates of drug resistance and relays in tuberculosis. N Engl J Med 1994; 330:1179–1184
    [Google Scholar]
20. Ellard G. A., Ellard D. R., Allen B. W. The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis. Am Rev Respir Dis 1986; 133:1076–1080
    [Google Scholar]
21. Acocella G., Luisetti M., Grassi G. G., Peona V., Pozzi E., Grassi C. Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy. Monaldi Arch Chest Dis 1993; 48:205–209
    [Google Scholar]
22. Geiter L. J., O’Brien R. J., Combs D. L., Snider D. E. United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide. Tubercle 1987; 68: Suppl 241–46
    [Google Scholar]
23. Sbarbaro J. A. A challenge—to our practices and to our principles. Tuber Lung Dis 1996; 77:2–3
    [Google Scholar]